DK1565471T3 - Quionolinylpyrazoler - Google Patents

Quionolinylpyrazoler

Info

Publication number: DK1565471T3
Authority: DK; Denmark
Prior art keywords: quionolinylpyrazoles; compound; administration; patient; formula
Prior art date: 2002-11-22

Application number

DK03768531T

Other languages

English (en)

Inventor

Jason Scott Sawyer

Jonathan Michael Yingling

Douglas Wade Beight

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-22

Filing date

2003-11-10

Publication date

2007-02-05

2003-11-10 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2007-02-05 Application granted granted Critical

2007-02-05 Publication of DK1565471T3 publication Critical patent/DK1565471T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Virology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK03768531T 2002-11-22 2003-11-10 Quionolinylpyrazoler DK1565471T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US42889302P	2002-11-22	2002-11-22
PCT/US2003/032747 WO2004048382A1 (en)	2002-11-22	2003-11-10	Quinolinyl-pyrrolopyrazoles

Publications (1)

Publication Number	Publication Date
DK1565471T3 true DK1565471T3 (da)	2007-02-05

Family

ID=32393478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03768531T DK1565471T3 (da)	2002-11-22	2003-11-10	Quionolinylpyrazoler

Country Status (28)

Country	Link
US (2)	US7265225B2 (da)
EP (1)	EP1565471B1 (da)
JP (1)	JP4542906B2 (da)
KR (1)	KR101057282B1 (da)
CN (1)	CN100345852C (da)
AT (1)	ATE341550T1 (da)
AU (1)	AU2003291643B2 (da)
BR (1)	BR0315337A (da)
CA (1)	CA2501322C (da)
CO (1)	CO5570677A2 (da)
CR (1)	CR7830A (da)
CY (1)	CY1106283T1 (da)
DE (1)	DE60308893T2 (da)
DK (1)	DK1565471T3 (da)
EA (1)	EA008387B1 (da)
EC (1)	ECSP055807A (da)
EG (1)	EG25822A (da)
ES (1)	ES2273046T3 (da)
HR (1)	HRP20050436B1 (da)
IL (1)	IL168190A (da)
MX (1)	MXPA05005432A (da)
NO (1)	NO331403B1 (da)
NZ (1)	NZ538942A (da)
PL (1)	PL227840B1 (da)
PT (1)	PT1565471E (da)
UA (1)	UA80571C2 (da)
WO (1)	WO2004048382A1 (da)
ZA (1)	ZA200503121B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR039241A1 (es)	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1567527A1 (en) *	2002-11-27	2005-08-31	Eli Lilly And Company	Condensed pyrazolo derivatives
MX2008001020A (es) *	2005-07-22	2008-03-25	Lilly Co Eli	Un monohidrato de pirrolo[1-2-b]pirazol piridin quinolin substituido como inhibidor de factor de crecimiento de transformacion-beta (tgf-beta).
WO2007039151A1 (en) *	2005-09-28	2007-04-12	Universität Zürich	Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
ES2647472T3 (es)	2006-10-03	2017-12-21	Genzyme Corporation	Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
KR20090066297A (ko) *	2006-10-16	2009-06-23	화이자 프로덕츠 인크.	치료용 피라졸릴 티에노피리딘
EP2588450B1 (en)	2010-07-02	2017-05-24	Gilead Sciences, Inc.	Napht-2-ylacetic acid derivatives to treat aids
SG186821A1 (en)	2010-07-02	2013-02-28	Gilead Sciences Inc	2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US8871744B2 (en)	2010-07-21	2014-10-28	B & G Partyers, LLC	Compounds and methods for selectively targeting tumor-associated mucins
SG194512A1 (en)	2011-04-21	2013-12-30	Gilead Sciences Inc	Benzothiazole compounds and their pharmaceutical use
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
IN2014DN03049A (da)	2011-10-26	2015-05-15	Seattle Childrens Res Inst
US9782452B2 (en)	2011-11-22	2017-10-10	Cornell University	Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
WO2013103738A1 (en)	2012-01-04	2013-07-11	Gilead Sciences, Inc.	Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en)	2012-01-04	2013-07-11	Gilead Sciences, Inc.	2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
CA2850881C (en)	2012-04-20	2021-02-16	Gilead Sciences, Inc.	Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
JP6449772B2 (ja)	2012-10-05	2019-01-09	カドモンコーポレイション，リミティドライアビリティカンパニー	ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
WO2014072517A1 (en)	2012-11-12	2014-05-15	Institució Catalana De Recerca I Estudis Avançats	Methods and kits for the prognosis of colorectal cancer
JO3336B1 (ar)	2014-10-07	2019-03-13	Lilly Co Eli	مركبات أمينو بيريديلوكسي بيرازول
TWI704151B (zh)	2014-12-22	2020-09-11	美商美國禮來大藥廠	Ｅｒｋ抑制劑
EP3250250A4 (en)	2015-01-30	2019-05-22	President and Fellows of Harvard College	PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
WO2016160881A1 (en)	2015-04-01	2016-10-06	Rigel Pharmaceuticals, Inc.	TGF-β INHIBITORS
JP6856648B2 (ja)	2015-12-15	2021-04-07	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃｘｃｒ４受容体アンタゴニスト
CN109548403A (zh) *	2016-07-07	2019-03-29	苏州科睿思制药有限公司	Galunisertib的晶型及其制备方法和用途
WO2018165979A1 (zh) *	2017-03-17	2018-09-20	杭州领业医药科技有限公司	2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
WO2018170724A1 (zh) *	2017-03-21	2018-09-27	杭州领业医药科技有限公司	2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
WO2019042383A1 (zh) *	2017-08-31	2019-03-07	苏州科睿思制药有限公司	Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) *	2017-11-30	2019-06-06	苏州科睿思制药有限公司	Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) *	2018-01-12	2019-07-18	苏州科睿思制药有限公司	Galunisertib的晶型及其制备方法和用途
WO2020019108A1 (en)	2018-07-23	2020-01-30	Guangzhou Othrotx Co., Ltd.	Bisphosphonate drug conjugates
CN113348167A (zh)	2018-12-27	2021-09-03	奈可萨斯医药有限公司	用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物
JP2022527972A (ja)	2019-04-02	2022-06-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	前悪性病変を有する患者において癌を予測及び予防する方法
WO2020248908A1 (zh) *	2019-06-10	2020-12-17	中国科学院广州生物医药与健康研究院	一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
WO2021142086A1 (en)	2020-01-08	2021-07-15	Synthis Therapeutics, Inc.	Alk5 inhibitor conjugates and uses thereof
CA3170142A1 (en)	2020-02-19	2021-08-26	Nammi Therapeutics, Inc.	Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2024258967A1 (en)	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anti-cd5 antibodies and their uses
GB202309553D0 (en)	2023-06-24	2023-08-09	Ucl Business Ltd	Compostions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356897A (en) *	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
PT1206474E (pt) *	1999-08-27	2004-10-29	Abbott Lab	Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
ES2289116T3 (es) *	2001-05-24	2008-02-01	Eli Lilly And Company	Nuevos derivados de pirrol como agentes farmaceuticos.
EP1567528A1 (en)	2002-11-21	2005-08-31	Eli Lilly And Company	Mixed lineage kinase modulators

2003
- 2003-10-11 UA UAA200504767A patent/UA80571C2/uk unknown
- 2003-11-10 DK DK03768531T patent/DK1565471T3/da active
- 2003-11-10 US US10/531,237 patent/US7265225B2/en not_active Expired - Fee Related
- 2003-11-10 EA EA200500859A patent/EA008387B1/ru not_active IP Right Cessation
- 2003-11-10 WO PCT/US2003/032747 patent/WO2004048382A1/en not_active Ceased
- 2003-11-10 DE DE60308893T patent/DE60308893T2/de not_active Expired - Lifetime
- 2003-11-10 PL PL376797A patent/PL227840B1/pl unknown
- 2003-11-10 HR HRP20050436AA patent/HRP20050436B1/hr not_active IP Right Cessation
- 2003-11-10 NZ NZ538942A patent/NZ538942A/en not_active IP Right Cessation
- 2003-11-10 PT PT03768531T patent/PT1565471E/pt unknown
- 2003-11-10 AU AU2003291643A patent/AU2003291643B2/en not_active Ceased
- 2003-11-10 JP JP2004555329A patent/JP4542906B2/ja not_active Expired - Fee Related
- 2003-11-10 KR KR1020057009199A patent/KR101057282B1/ko not_active Expired - Fee Related
- 2003-11-10 AT AT03768531T patent/ATE341550T1/de active
- 2003-11-10 BR BR0315337-1A patent/BR0315337A/pt not_active Application Discontinuation
- 2003-11-10 MX MXPA05005432A patent/MXPA05005432A/es active IP Right Grant
- 2003-11-10 CA CA2501322A patent/CA2501322C/en not_active Expired - Fee Related
- 2003-11-10 ES ES03768531T patent/ES2273046T3/es not_active Expired - Lifetime
- 2003-11-10 EP EP03768531A patent/EP1565471B1/en not_active Expired - Lifetime
- 2003-11-10 CN CNB2003801038400A patent/CN100345852C/zh not_active Expired - Fee Related
2005
- 2005-04-18 ZA ZA200503121A patent/ZA200503121B/en unknown
- 2005-04-21 IL IL168190A patent/IL168190A/en active IP Right Grant
- 2005-05-06 CR CR7830A patent/CR7830A/es unknown
- 2005-05-18 CO CO05048136A patent/CO5570677A2/es active IP Right Grant
- 2005-05-18 EG EGNA2005000237 patent/EG25822A/xx active
- 2005-05-19 EC EC2005005807A patent/ECSP055807A/es unknown
- 2005-06-21 NO NO20053045A patent/NO331403B1/no not_active IP Right Cessation
2006
- 2006-12-08 CY CY20061101769T patent/CY1106283T1/el unknown
2007
- 2007-07-25 US US11/782,659 patent/US7834029B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT1565471E (pt)	2007-01-31
WO2004048382A1 (en)	2004-06-10
HRP20050436B1 (hr)	2013-11-08
ZA200503121B (en)	2006-07-26
US20060040983A1 (en)	2006-02-23
EA008387B1 (ru)	2007-04-27
IL168190A (en)	2011-01-31
NO331403B1 (no)	2011-12-19
HRP20050436A2 (en)	2005-10-31
DE60308893D1 (de)	2006-11-16
AU2003291643B2 (en)	2010-05-13
CR7830A (es)	2005-06-20
MXPA05005432A (es)	2005-08-03
BR0315337A (pt)	2005-08-16
CN1714090A (zh)	2005-12-28
DE60308893T2 (de)	2007-03-15
ECSP055807A (es)	2005-08-11
EP1565471B1 (en)	2006-10-04
PL376797A1 (pl)	2006-01-09
CA2501322A1 (en)	2004-06-10
NZ538942A (en)	2007-01-26
UA80571C2 (en)	2007-10-10
EA200500859A1 (ru)	2005-10-27
PL227840B1 (pl)	2018-01-31
CY1106283T1 (el)	2011-10-12
CN100345852C (zh)	2007-10-31
KR20050083945A (ko)	2005-08-26
CO5570677A2 (es)	2005-10-31
CA2501322C (en)	2011-05-10
HK1081948A1 (en)	2006-05-26
NO20053045L (no)	2005-06-21
AU2003291643A1 (en)	2004-06-18
US7834029B2 (en)	2010-11-16
ES2273046T3 (es)	2007-05-01
ATE341550T1 (de)	2006-10-15
EG25822A (en)	2012-08-23
JP4542906B2 (ja)	2010-09-15
KR101057282B1 (ko)	2011-08-16
EP1565471A1 (en)	2005-08-24
US20080027102A1 (en)	2008-01-31
JP2006514012A (ja)	2006-04-27
US7265225B2 (en)	2007-09-04

Publication	Publication Date	Title
ATE341550T1 (de)	2006-10-15	Quinolinyl-pyrrolopyrazole
SG2013013339A (en)	2014-12-30	N3 alkylated benzimidazole derivatives as mek inhibitors
TNSN06032A1 (en)	2007-10-03	Pyridazine derivatives and their use as therapeutic agents
WO2005023759A3 (en)	2005-09-22	Heterocyclic inhibitors of mek and methods of use thereof
EA200501849A1 (ru)	2006-06-30	Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CY1111721T1 (el)	2015-10-07	Ακυλαμινοπυραζολια ως αναστολεις fgfr
SE0401345D0 (sv)	2004-05-25	Therapeutic compounds: Pyridine as scaffold
MY141939A (en)	2010-07-30	Pyridazine derivatives and their use as therapeutic agents
SE0401342D0 (sv)	2004-05-25	Therapeutic compounds
IS2696B (is)	2010-11-15	Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
SE9900961D0 (sv)	1999-03-16	Novel compounds
NO20032027L (no)	2003-07-04	Effektive antitumorbehandlinger
PT1390371E (pt)	2006-07-31	Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
BRPI0409959A (pt)	2006-04-25	uso de derivados de azetidinacarboxamida em terapia
ATE303384T1 (de)	2005-09-15	1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
GB0130677D0 (en)	2002-02-06	Medicaments and novel compounds
DK1689404T3 (da)	2009-01-26	Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors
PT1039900E (pt)	2004-09-30	Agentes terapeuticos
CY1107465T1 (el)	2012-12-19	Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
NO20031410D0 (no)	2003-03-27	Antitumorterapi innbefattende distamycinderivater
ATE421882T1 (de)	2009-02-15	Schnellösliches azithromycin in einzeldosisform
GEP201606538B (en)	2016-09-12	Preoperative treatment of post operative pain
MXPA01012936A (es)	2004-04-21	Composicion farmaceutica que contiene sibutramina y orlistat.
ATE343576T1 (de)	2006-11-15	7-azaindolderivate als cox2-inhibitoren